Telavancin Pediatric PK Study (Ages >3 Months to 17 Years)
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants, children,
and adolescents will receive a single 10 mg/kg dose of telavancin infused intravenously (IV)
over 60 minutes
Phase:
Phase 4
Details
Lead Sponsor:
Cumberland Pharmaceuticals Theravance Biopharma Antibiotics, Inc.